CN112057559A - Application of dendrobium huoshanense extract in medicine for preventing, relieving and/or treating uric acid renal disease - Google Patents
Application of dendrobium huoshanense extract in medicine for preventing, relieving and/or treating uric acid renal disease Download PDFInfo
- Publication number
- CN112057559A CN112057559A CN202011078308.XA CN202011078308A CN112057559A CN 112057559 A CN112057559 A CN 112057559A CN 202011078308 A CN202011078308 A CN 202011078308A CN 112057559 A CN112057559 A CN 112057559A
- Authority
- CN
- China
- Prior art keywords
- dendrobium huoshanense
- preparation
- uric acid
- dendrobium
- aqueous extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 239000000284 extract Substances 0.000 title claims abstract description 28
- 241001678082 Dendrobium huoshanense Species 0.000 title claims description 75
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract description 15
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract description 14
- 229940116269 uric acid Drugs 0.000 title abstract description 14
- 208000017169 kidney disease Diseases 0.000 title description 3
- 206010046337 Urate nephropathy Diseases 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims description 27
- 239000006286 aqueous extract Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 8
- 201000001431 Hyperuricemia Diseases 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 15
- 201000005569 Gout Diseases 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 241001523681 Dendrobium Species 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 6
- 239000004575 stone Substances 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000009278 visceral effect Effects 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229950000193 oteracil Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- -1 purine alcohols Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a natural medicine extract for preventing or treating uric acid nephropathy and gout. The preparation is prepared by extracting effective components from dendrobium and is characterized in that the preparation is prepared by extracting dendrobium with water. The traditional Chinese medicine composition has stable effect and moderate dendrobium concentration, and animal experiments prove that the traditional Chinese medicine composition can effectively prevent or treat uric acid nephropathy and gout, has good effect of regulating the uric acid level in vivo, and provides a new product for clinically preventing or treating uric acid nephropathy and gout.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to application of dendrobium huoshanense in preventing, relieving and/or treating uric acid nephropathy.
Background
Uric acid nephropathy is a purine metabolic disorder disease caused by excessive production of uric acid in vivo and/or reduction of uric acid excretion of kidney, easily causes urate to deposit on bone joints, kidney, subcutaneous parts and the like, and causes various major diseases such as acute and chronic gouty arthritis, myocardial infarction, coronary heart disease, diabetes, hyperlipidemia, metabolic syndrome, chronic kidney disease and the like.
In recent years, with the change of urbanization, the change of living eating habits and the aggravation of aging of population, the incidence rate of uric acid nephropathy in China is increased year by year, and the rare diseases become epidemic diseases. According to epidemiological investigation results of partial regions, the prevalence rate of uric acid nephropathy in China is estimated to be 5.5% -19.3%, and is still increasing. Therefore, the development of a highly effective drug for the treatment of uric acid nephropathy is in the forefront.
At present, the first-line medicine clinically used for reducing uric acid is purine alcohol, but the purine alcohol can cause adverse reactions such as skin allergy, bone marrow suppression and the like. In addition, purine alcohols are metabolized by the kidney and it is often necessary to adjust the dose to glomerular filtration for patients with renal insufficiency. The febuxostat has light side effect and the most effective clinical application amount of febuxostat with guaranteed treatment safety performance does not form a unified standard. Therefore, at present, western medicines lack a radical cure means and have certain side effects, so that the clinical application is limited. Therefore, we tried to find a natural drug for uric acid nephropathy, which can not only avoid side effects to the maximum extent, but also can effectively treat uric acid nephropathy.
Dendrobium huoshanense (Dendrobium huoshanense) is a perennial herb plant of the genus Dendrobium of the family Orchidaceae, the medicinal value and the health care function of which are recorded and exemplified in the classic of the herbal of the past generations, and according to the record of supplement herbal treatise, "Hu comes out of Huoshan, nourishes stomach and clears heat, produces body fluid to quench thirst, clears away deficient heat, and has comprehensive success. Relevant experimental results show that the dendrobium huoshanense has the medicinal characteristics of sweet and cold property, and yin nourishing and heat clearing, but the dendrobium huoshanense extract is not reported in the aspect of preparing the preparation for treating uric acid nephropathy.
Disclosure of Invention
Based on the above current situation, the present invention aims to provide a preparation prepared from a traditional Chinese medicine extract for effectively treating uric acid nephropathy from the perspective of traditional Chinese medicine. The technical scheme of the invention is as follows:
the first purpose of the invention is to provide a dendrobium huoshanense aqueous extract which is characterized by being prepared by the following method:
weighing dendrobium huoshanense medicinal materials, removing leaves and taking stems, cutting into small segments, adding water with the volume being 10-10.5 times of that of the medicinal materials, directly heating without soaking, heating and refluxing for 1-1.1 hours, filtering, taking filter residues, refluxing for 1-1.1 hours, filtering, combining two extracting solutions, concentrating until the concentration of the crude drug is 0.123-0.493 g/ml, directly diluting the crude drug to be low concentration from high concentration in the practical implementation process, or concentrating the crude drug to be high concentration to obtain dendrobium huoshanense aqueous extract, and concentrating the dendrobium huoshanense aqueous extract to obtain clear paste with the relative density of 1.25-1.30.
Preferably, the dendrobium huoshanense medicinal material is weighed, leaves and stems are removed, the dendrobium huoshanense medicinal material is cut into small segments, water with the volume being 10 times of that of the medicinal material is added, the dendrobium huoshanense medicinal material is directly heated without soaking, the dendrobium huoshanense medicinal material is heated and refluxed for 1 hour, filter residue is taken after the dendrobium huoshanense medicinal material is filtered, two extracting solutions are combined after the dendrobium huoshanense medicinal material is refluxed for 1 hour, and the extract is concentrated until the concentration of the crude drug is 0.123 g/.
In a special embodiment, the mixture is concentrated to the crude drug concentration of 0.123g/ml to obtain dendrobium huoshanense aqueous extract;
in a special embodiment, the mixture is concentrated to the crude drug concentration of 0.247g/ml to obtain dendrobium huoshanense aqueous extract;
in a specific embodiment, the mixture is concentrated to a crude drug concentration of 0.493g/ml, and the dendrobium huoshanense aqueous extract is obtained.
The second purpose of the invention is to provide a preparation containing the dendrobium huoshanense aqueous extract in claim 1.
Furthermore, the dosage of the preparation is 1.23-4.93 g of the crude drug of dendrobium huoshanense/kg of the body weight of a patient.
In a particular embodiment, the dosage of the preparation is 4.93g of the crude drug of dendrobium huoshanense/kg of the body weight of the patient;
in a particular embodiment, the dosage of the preparation is 2.47g of the crude drug of dendrobium huoshanense/kg of the body weight of a patient;
in a particular embodiment, the formulation is administered at a dose of 1.23g of the crude drug of dendrobium huoshanense per kg of patient body weight.
Further, the preparation comprises dendrobium huoshanense extract and pharmaceutically acceptable auxiliary materials or auxiliary components.
Further, the preparation is powder, tablets, granules, capsules, pills, paste, powder and injection.
The third purpose of the invention is to provide a food or health care product for preventing, relieving and/or treating the uric acid nephropathy, wherein the food or health care product comprises the dendrobium huoshanense aqueous extract.
Furthermore, the food or the health-care product is prepared by preparing the dendrobium huoshanense aqueous extract into a drink or preparing the dendrobium huoshanense aqueous extract into a corresponding forming mode after extraction.
The fourth purpose of the invention is to provide the application of the dendrobium huoshanense aqueous extract, the preparation or the food or health care product in preparing the medicine for preventing, relieving and/or treating the uric acid nephropathy.
The fifth purpose of the invention is to provide the application of the dendrobium huoshanense aqueous extract, the preparation or the food or health care product in preparing the medicine for preventing, relieving and/or treating hyperuricemia.
The sixth purpose of the invention is to provide an application of the dendrobium huoshanense aqueous extract, the preparation or the food or the health care product in preparing a medicine for preventing, relieving and/or treating common complications of hyperuricemia, such as cardiovascular diseases of gouty arthritis, myocardial infarction, angina pectoris and the like.
In the three applications, the dosage of the preparation is 1.23-4.93 g of the crude drug of dendrobium huoshanense/kg of the body weight of a patient.
In a particular embodiment, the dosage of the preparation is 4.93g of the crude drug of dendrobium huoshanense/kg of the body weight of the patient;
in a particular embodiment, the dosage of the preparation is 2.47g of the crude drug of dendrobium huoshanense/kg of the body weight of a patient;
in a particular embodiment, the formulation is administered at a dose of 1.23g of the crude drug of dendrobium huoshanense per kg of patient body weight.
The invention is used for treating kidney damage caused by hyperuricemia or reduction of excretion to form uric acid nephropathy, and clinical manifestations of the kidney damage include uric acid calculus, small molecule proteinuria, edema, nocturia, hypertension, rise in blood uric acid and renal tubule function damage.
Further, the drug for preventing, alleviating and/or treating uric acid nephropathy can relieve liver atrophy caused by uric acid nephropathy.
Further, the medicament for preventing, alleviating and/or treating the uric acid nephropathy can relieve splenomegaly caused by the uric acid nephropathy.
Further, the medicine for preventing, relieving and/or treating uric acid nephropathy can reduce the content of uric acid, urea nitrogen and creatinine in uric acid nephropathy patients.
The term "pharmaceutically acceptable" refers to a carrier, diluent, excipient, and/or salt, ester formed, which is generally chemically or physically compatible with the other ingredients comprising a pharmaceutical dosage form and with the recipient.
The Dendrobium huoshanense of the invention is Dendrobii Huoshanense
[ SOURCE ] fresh or dried stem of Dendrobium huoshanense D.houshanense (Dendrobium huoshanense) belonging to the family Orchidaceae.
[ PRODUCTION ZO ] produced in HOOSHAN county, Anhui province, in Dabie mountain areas.
[ EFFECT ] has effects of improving eyesight, harmonizing yin and yang, tonifying yang, invigorating kidney, caring skin, and retaining youthful looks.
Compared with the prior art, the technical scheme of the invention has the following beneficial effects: provides a new drug choice for the treatment of uric acid nephropathy. The composition has no obvious toxic or side effect, definite curative effect, safety and controllability, low price and easy obtainment.
Detailed Description
The following examples are presented to enable those skilled in the art to more fully understand the present invention and are not intended to limit the invention in any way. The raw materials and equipment used are known products and can be obtained commercially.
According to the 'Chinese pharmacopoeia' of 2015 edition, the daily dose of the mice is 2.47g/kg according to a body surface area conversion algorithm, and if the dose is used as the middle dose of the experiment, twice of the dose is taken as the high dose (4.93g/kg), and 1/2 is taken as the low dose (1.23 g/kg).
Experimental animals: kunming mice (SPF grade, male, 20 + -2 g) were fed with normal feed without restriction of drinking water.
An experimental model: mouse uric acid nephropathy model.
Grouping experiments: the total number of the groups is 6, and each group comprises 8 groups which are respectively as follows: normal group, model group, positive group, dendrobium huoshanense water extract low dose group (hereinafter referred to as stone low group), dendrobium huoshanense water extract medium dose group (hereinafter referred to as stone medium group), and dendrobium huoshanense water extract high dose group (hereinafter referred to as stone high group).
The experimental method comprises the following steps: the Kunming mice are randomly grouped and numbered, and each group comprises 8 mice, namely a normal group, a model group, a positive group, a dendrobium huoshanense water extract low-dose group, a dendrobium huoshanense water extract medium-dose group and a dendrobium huoshanense water extract high-dose group. All mice were gavaged for one week once a day. One hour after the last administration, the eyeball was picked up and blood was taken out and serum was separated, and immediately after the blood was taken, cervical dislocation was sacrificed and relevant organs were separated. And (6) carrying out relevant data determination and analysis.
The experimental steps are as follows:
1. kunming mice were grouped and labeled, weighed.
2. Preparing the medicine: uniformly dispersing potassium oxonate (250mg/kg) with the purity of more than or equal to 98 percent in distilled water; positive drugs: uniformly dispersing allopurinol (5mg/kg) with the purity of more than or equal to 98 percent in distilled water; water extract of dendrobium huoshanense: taking a proper amount of dendrobium huoshanense, removing leaves and taking stems according to a material-liquid ratio of 1:10, cutting into small segments, adding water with the volume of 10 times of that of the medicinal materials, heating and refluxing for 1h, extracting twice, combining extracting solutions, concentrating to 0.493g/ml, sequentially diluting to obtain a medium dose of the dendrobium huoshanense water extract and a low dose of the dendrobium huoshanense water extract, cooling, and storing in a refrigerator for later use.
3. The model group, the positive group and each drug group are modeled according to weight intragastric potassium oxonate (250 mg/kg). Thirty minutes after molding, the positive group is filled with gastric allopurinol (10mg/kg), and three groups of drug groups are filled with gastric test extracts with different dosages (the low dosage of the dendrobium huoshanense water extract is 1.23g/kg, the dosage of the dendrobium huoshanense water extract is 2.47g/kg, and the high dosage of the dendrobium huoshanense water extract is 4.93 g/kg). Weigh daily and record data.
4. The experiment was performed one week after the continuous administration and one hour after the last administration.
5. The mice were bled from the eyes to obtain about 1ml of blood. Centrifuging at 2500r/min for 10min at 4 deg.C, collecting supernatant, and freezing in 200 μ L per tube in-20 deg.C refrigerator for detecting corresponding biochemical indexes including Uric Acid (UA), urea nitrogen (BUN) and creatinine (SCR).
6. After blood sampling, cervical dislocation was immediately sacrificed and heart, liver, spleen, lung, kidney, brain were dissected and separated on an ice bench and weighed for recording.
The experimental results are as follows: SPSS and Excel are adopted to analyze uric acid content, visceral brain coefficient, visceral coefficient and the like to generate an orthogonal table, and all data are expressed in the following order
Indicating that LSD was used to test for significance.
Table 1 visceral brain coefficients:
data result use
Is represented by, n is 8
In comparison with the normal group,#P＜0.05，##P＜0.01，###P＜0.001
comparing with model group, P < 0.05, P < 0.01, P < 0.001
The data in table 1 are comparisons of the coefficients of the brains of 8 mice per group, tested for significance with LSD. As can be seen from Table 1: the urinary acid nephropathy causes the ratio of the liver, the spleen and the brain of the sick mice, and the normal group and the model group have significant difference; the high, medium and low doses of the dendrobium huoshanense aqueous extract can obviously relieve the conditions of liver atrophy and splenomegaly caused by uric acid nephropathy. The data show that the dendrobium huoshanense water extract has certain effect of relieving and treating visceral problems caused by uric acid nephropathy.
Table 2 organ coefficients:
data result use
Is represented by, n is 8
In comparison with the normal group,#P＜0.05，##P＜0.01，###P＜0.001
the data in table 2 are comparisons of organ coefficients for 8 mice per group, and significance was checked by LSD. As can be seen from Table 2: in the organ coefficients, the stone low group, the stone middle group and the stone high group have no significant difference (P is more than 0.05) with the normal group, and the dendrobium huoshanense water extract has no obvious damage to other organs of the mouse.
Table 3 biochemical indices:
data result use
Is represented by, n is 8
In comparison with the normal group,#P＜0.05，##P＜0.01，###P＜0.001
comparing with model group, P < 0.05, P < 0.01, P < 0.001
In the biochemical indexes shown in Table 3, the model group is significantly different from the normal group (P is less than 0.05), which indicates that the modeling is successful. Uric acid nephropathy leads to significantly increased levels of uric acid, creatinine and urea nitrogen in the serum of affected mice. The high-dose group of the dendrobium huoshanense aqueous extract has significant difference with the model group, and the treatment effect is close to the positive group, which shows that the dendrobium huoshanense aqueous extract has better curative effect on the treatment of uric acid nephropathy.
The results show that the dendrobium huoshanense water extract can achieve the effect of reducing uric acid, creatinine and urea nitrogen in serum similar to allopurinol. The treatment effect is more obvious along with the increase of the concentration of the dendrobium huoshanense water extract, which shows that the concentration of the dendrobium huoshanense water extract is properly changed to obtain better treatment effect.
The dendrobium huoshanense water extract has no obvious damage to organs, can relieve organ damage to a certain extent, and shows that the dendrobium huoshanense water extract has a good prospect in clinical application.
The above is only a preferred embodiment of the present invention, and it should be noted that the above preferred embodiment should not be considered as limiting the present invention, and the protection scope of the present invention should be subject to the scope defined by the claims. It will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the spirit and scope of the invention, and such modifications and adaptations are intended to be within the scope of the invention.
Claims (10)
1. The dendrobium huoshanense aqueous extract is characterized by being prepared by the following method:
weighing dendrobium huoshanense medicinal materials, removing leaves and taking stems, cutting into small segments, adding water with the volume being 10-10.5 times of that of the medicinal materials, heating and refluxing for 1-1.1 hours, filtering, taking filter residues, refluxing for 1-1.1 hours, filtering, combining extracting solutions obtained in two times, and concentrating until the concentration of crude drugs is 0.123-0.493 g/ml to obtain the dendrobium huoshanense aqueous extract.
2. A formulation comprising the aqueous extract of Dendrobium huoshanense of claim 1.
3. The preparation of claim 2, wherein the preparation is administered at a dose of 1.23-4.93 g crude drug of dendrobium huoshanense per kg of patient body weight.
4. The preparation of claim 2, wherein the preparation is administered at a dose of 4.93g crude drug of dendrobium huoshanense per kg of patient body weight, or 2.47g crude drug of dendrobium huoshanense per kg of patient body weight, or 1.23g crude drug of dendrobium huoshanense per kg of patient body weight.
5. The preparation of claim 2, wherein the preparation comprises the dendrobium huoshanense extract and pharmaceutically acceptable auxiliary materials or auxiliary components.
6. The formulation of claim 2, wherein the formulation is a powder, tablet, granule, capsule, pill, paste, powder, injection.
7. A food or health care product for preventing, alleviating and/or treating uric acid nephropathy, wherein the food or health care product comprises the dendrobium huoshanense aqueous extract according to claim 1.
8. Use of an aqueous extract of dendrobium huoshanense as claimed in claim 1, or a formulation as claimed in claim 2, or a food or health product as claimed in claim 7 for the preparation of a medicament for the prevention, alleviation and/or treatment of uric acid nephropathy.
9. Use of an aqueous extract of dendrobium huoshanense as claimed in claim 1, or a formulation as claimed in claim 2, or a food or health product as claimed in claim 7 for the preparation of a medicament for the prevention, alleviation and/or treatment of hyperuricemia.
10. Use of an aqueous extract of dendrobium huoshanense as claimed in claim 1, or a formulation as claimed in claim 2, or a food or health product as claimed in claim 7 for the preparation of a medicament for the prevention, alleviation and/or treatment of complications of hyperuricemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011078308.XA CN112057559A (en) | 2020-10-10 | 2020-10-10 | Application of dendrobium huoshanense extract in medicine for preventing, relieving and/or treating uric acid renal disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011078308.XA CN112057559A (en) | 2020-10-10 | 2020-10-10 | Application of dendrobium huoshanense extract in medicine for preventing, relieving and/or treating uric acid renal disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112057559A true CN112057559A (en) | 2020-12-11 |
Family
ID=73655003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011078308.XA Pending CN112057559A (en) | 2020-10-10 | 2020-10-10 | Application of dendrobium huoshanense extract in medicine for preventing, relieving and/or treating uric acid renal disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112057559A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112022966A (en) * | 2020-10-10 | 2020-12-04 | 中国药科大学 | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383292A (en) * | 2014-10-31 | 2015-03-04 | 南京葆赫生物技术有限公司 | Application of dendrobium officinale extract in preparation of medicine for preventing and/or treating hyperuricemia |
| CN104740335A (en) * | 2013-12-30 | 2015-07-01 | 浙江中医药大学 | Dendrobium officinale leaf extract with uric acid reducing function and application of dendrobium officinale leaf extract |
-
2020
- 2020-10-10 CN CN202011078308.XA patent/CN112057559A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740335A (en) * | 2013-12-30 | 2015-07-01 | 浙江中医药大学 | Dendrobium officinale leaf extract with uric acid reducing function and application of dendrobium officinale leaf extract |
| CN104383292A (en) * | 2014-10-31 | 2015-03-04 | 南京葆赫生物技术有限公司 | Application of dendrobium officinale extract in preparation of medicine for preventing and/or treating hyperuricemia |
Non-Patent Citations (2)
| Title |
|---|
| 张静等: "霍山石斛提取物对人喉癌细胞Hep-2增殖和凋亡的影响及其机制", 《中国生物制品学杂志》 * |
| 霍山固本堂石斛: "四高的标准是什么？看看霍山石斛的神奇功效", 《HTTPS://MP.WEIXIN.QQ.COM/S/KYE8O41PSGZE1YN95HYQYQ》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112022966A (en) * | 2020-10-10 | 2020-12-04 | 中国药科大学 | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia |
| CN112022966B (en) * | 2020-10-10 | 2022-03-08 | 中国药科大学 | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| EP3151843B1 (en) | Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof | |
| CN112057559A (en) | Application of dendrobium huoshanense extract in medicine for preventing, relieving and/or treating uric acid renal disease | |
| KR101416453B1 (en) | A medicine composition for treating bronchial asthma and preparative method thereof | |
| KR20170027914A (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
| KR20190033828A (en) | Compositions for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising herbal extracts | |
| CN111991436A (en) | Application of atractylis lancea aqueous extract in preparation of medicine for preventing, relieving and/or treating hyperuricemia | |
| CN105168846A (en) | Oral composition with physiological function | |
| KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
| CN112022966B (en) | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia | |
| CN114947129A (en) | Uric acid-reducing cichorium grandiflorum and angelica dahurica health food and preparation method thereof | |
| CN1313112C (en) | Medicinal composition with nourishing and tranquilizing | |
| CN114747766A (en) | Health-care food composition capable of reducing uric acid and preparation method and application thereof | |
| CN113384612A (en) | Anti-gout composition and preparation method and application thereof | |
| CN108379455B (en) | Uric acid reducing composition | |
| KR101330687B1 (en) | Composition for treating and preventing obesity containing oriental herbal extracts | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN114246910A (en) | Traditional Chinese medicine composition for treating gout and application thereof | |
| CN1261151C (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN107029092A (en) | A kind of mare's milk sugar-reduction traditional Chinese medicine composition and its preparation method and application | |
| CN112057476B (en) | Composition and application thereof in sobering-up, hangover-relieving and stomach-protecting | |
| CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
| CN112674327B (en) | Health-care food | |
| CN101164595A (en) | Traditional Chinese medicine for curing anorexia | |
| CN1204916C (en) | Medicine for treating depression and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201211 |